<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CD44 is a polymorphic cell surface <z:chebi fb="2" ids="17089">glycoprotein</z:chebi>, currently proposed to be the principal cell surface receptor for hyaluronan </plain></SENT>
<SENT sid="1" pm="."><plain>However, different isoforms of CD44, expressed in human <z:mp ids='MP_0002022'>lymphoid tumor</z:mp> cells, appear to have distinct effects on the ability of the cells to attach to hyaluronan-coated surfaces and on their capacity to form <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we address the mechanisms that may regulate CD44 isoform-dependent <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to hyaluronan </plain></SENT>
<SENT sid="3" pm="."><plain>We use a human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, stably transfected with six different alternatively spliced human CD44 isoforms, to determine their potential hyaluronan binding and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> promoting roles </plain></SENT>
<SENT sid="4" pm="."><plain>We show that transfectants expressing CD44 splice variants that contain variable exons 6-10, 7-10 and 8-10 adhere to hyaluronan-coated surfaces weakly and that corresponding <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation in vivo is delayed with respect to CD44-negative parental cell-derived <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Abundant shedding of these three isoforms may play a significant role in determining the rate of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development </plain></SENT>
<SENT sid="6" pm="."><plain>Transfectants expressing variable exon 3, on the other hand, fail to display CD44-mediated <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to hyaluronan, but form <z:e sem="disease" ids="C0282609" disease_type="Neoplastic Process" abbrv="">bone marrow tumors</z:e> rapidly following intravenous injection </plain></SENT>
<SENT sid="7" pm="."><plain>These observations suggest that different mechanisms regulate CD44-mediated <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>, and provide evidence that expression of exon v3 may confer novel ligand-binding properties </plain></SENT>
</text></document>